BACKGROUND: The mechanisms underlying smallpox vaccine-induced variations in immune responses are not well understood, but are of considerable interest to a deeper understanding of poxvirus immunity and correlates of protection. METHODS: We assessed transcriptional messenger RNA expression changes in 197 recipients of primary smallpox vaccination representing the extremes of humoral and cellular immune responses. RESULTS: The 20 most significant differentially expressed genes include a tumor necrosis factor-receptor superfamily member, an interferon (IFN) gene, a chemokine gene, zinc finger protein genes, nuclear factors, and histones (P ≤ 1.06E(-20), q ≤ 2.64E(-17)). A pathway analysis identified 4 enriched pathways with cytokine production by the T-helper 17 subset of CD4+ T cells being the most significant pathway (P = 3.42E(-05)). Two pathways (antiviral actions of IFNs, P = 8.95E(-05); and IFN-α/β signaling pathway, P = 2.92E(-04)), integral to innate immunity, were enriched when comparing high with low antibody responders (false discovery rate, < 0.05). Genes related to immune function and transcription (TLR8, P = .0002; DAPP1, P = .0003; LAMP3, P = 9.96E(-05); NR4A2, P ≤ .0002; EGR3, P = 4.52E(-05)), and other genes with a possible impact on immunity (LNPEP, P = 3.72E(-05); CAPRIN1, P = .0001; XRN1, P = .0001), were found to be expressed differentially in high versus low antibody responders. CONCLUSION: We identified novel and known immunity-related genes and pathways that may account for differences in immune response to smallpox vaccination.
BACKGROUND: The mechanisms underlying smallpox vaccine-induced variations in immune responses are not well understood, but are of considerable interest to a deeper understanding of poxvirus immunity and correlates of protection. METHODS: We assessed transcriptional messenger RNA expression changes in 197 recipients of primary smallpox vaccination representing the extremes of humoral and cellular immune responses. RESULTS: The 20 most significant differentially expressed genes include a tumor necrosis factor-receptor superfamily member, an interferon (IFN) gene, a chemokine gene, zinc finger protein genes, nuclear factors, and histones (P ≤ 1.06E(-20), q ≤ 2.64E(-17)). A pathway analysis identified 4 enriched pathways with cytokine production by the T-helper 17 subset of CD4+ T cells being the most significant pathway (P = 3.42E(-05)). Two pathways (antiviral actions of IFNs, P = 8.95E(-05); and IFN-α/β signaling pathway, P = 2.92E(-04)), integral to innate immunity, were enriched when comparing high with low antibody responders (false discovery rate, < 0.05). Genes related to immune function and transcription (TLR8, P = .0002; DAPP1, P = .0003; LAMP3, P = 9.96E(-05); NR4A2, P ≤ .0002; EGR3, P = 4.52E(-05)), and other genes with a possible impact on immunity (LNPEP, P = 3.72E(-05); CAPRIN1, P = .0001; XRN1, P = .0001), were found to be expressed differentially in high versus low antibody responders. CONCLUSION: We identified novel and known immunity-related genes and pathways that may account for differences in immune response to smallpox vaccination.
Authors: Samuel L Stanley; Sharon E Frey; Patricia Taillon-Miller; Jianhua Guo; Raymond D Miller; Daniel C Koboldt; Michael Elashoff; Ryan Christensen; Nancy L Saccone; Robert B Belshe Journal: J Infect Dis Date: 2007-06-04 Impact factor: 5.226
Authors: Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Robert A Vierkant; Robert M Jacobson; Margaret A K Ryan; Gregory A Poland Journal: Vaccine Date: 2009-02-05 Impact factor: 3.641
Authors: Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; Beth R Larrabee; V Shane Pankratz; Gregory A Poland Journal: Hum Immunol Date: 2013-06-24 Impact factor: 2.850
Authors: Scott D Painter; Iana H Haralambieva; Inna G Ovsyannikova; Diane E Grill; Gregory A Poland Journal: Viral Immunol Date: 2014-03 Impact factor: 2.257
Authors: Andrew J Gartland; Sue Li; John McNevin; Georgia D Tomaras; Raphael Gottardo; Holly Janes; Youyi Fong; Daryl Morris; Daniel E Geraghty; Gustavo H Kijak; Paul T Edlefsen; Nicole Frahm; Brendan B Larsen; Sodsai Tovanabutra; Eric Sanders-Buell; Allan C deCamp; Craig A Magaret; Hasan Ahmed; Jodie P Goodridge; Lennie Chen; Philip Konopa; Snehal Nariya; Julia N Stoddard; Kim Wong; Hong Zhao; Wenjie Deng; Brandon S Maust; Meera Bose; Shana Howell; Adam Bates; Michelle Lazzaro; Annemarie O'Sullivan; Esther Lei; Andrea Bradfield; Grace Ibitamuno; Vatcharain Assawadarachai; Robert J O'Connell; Mark S deSouza; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Merlin L Robb; John Sidney; Alessandro Sette; Susan Zolla-Pazner; David Montefiori; M Juliana McElrath; James I Mullins; Jerome H Kim; Peter B Gilbert; Tomer Hertz Journal: J Virol Date: 2014-05-14 Impact factor: 5.103
Authors: Richard B Kennedy; Gregory A Poland; Inna G Ovsyannikova; Ann L Oberg; Yan W Asmann; Diane E Grill; Robert A Vierkant; Robert M Jacobson Journal: Vaccine Date: 2016-05-11 Impact factor: 3.641
Authors: Edione C Reis; Lais T da Silva; Wanessa C da Silva; Alexandre Rios; Alberto J Duarte; Telma M Oshiro; Sergio Crovella; Alessandra Pontillo Journal: Hum Vaccin Immunother Date: 2018-05-17 Impact factor: 3.452
Authors: Whitney L Simon; Hannah M Salk; Inna G Ovsyannikova; Richard B Kennedy; Gregory A Poland Journal: Immunotherapy Date: 2014 Impact factor: 4.196
Authors: Gregory A Poland; Richard B Kennedy; Brett A McKinney; Inna G Ovsyannikova; Nathaniel D Lambert; Robert M Jacobson; Ann L Oberg Journal: Semin Immunol Date: 2013-06-05 Impact factor: 11.130